Postbiotics

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Recent postbiotic research has focused heavily on clarifying terminology and defining what constitutes a postbiotic, driven by inconsistent usage in the literature and marketplace. ISAPP’s consensus definition (a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”) has become a central reference point, emphasizing that inactivated microbial cells or cell components must be present, with or without metabolites, and that a demonstrated health benefit is required. Beyond definition work, the most studied biological areas are gut health and the gut microbiota–immune axis, including immunomodulation, anti-inflammatory effects, gut barrier function, and microbiota-related mechanisms. A substantial portion of the applied literature also targets metabolic diseases (notably obesity and type 2 diabetes) and broader disease contexts linked to dysbiosis, with mechanistic attention to microbial metabolites (e.g., short-chain fatty acids), antimicrobial compounds, and structural cell components (e.g., cell wall fragments, teichoic acids, extracellular polysaccharides).

The strongest evidence supported across these abstracts is that non-viable microbial preparations and their components can plausibly confer host benefits through defined mechanistic pathways—particularly modulation of immune responses, reduction of inflammation, and improvement of intestinal barrier integrity—while potentially reducing some risks associated with administering live microorganisms. Reviews consistently indicate that postbiotics (and related probiotic-derived products) can influence host physiology via microbial metabolites and cell-associated molecular patterns, and that clinical studies are emerging in areas such as metabolic disease management. However, the evidence base is described as uneven: while mechanistic and preclinical findings are extensive, clinical efficacy is not uniformly established across products or indications, and in many cases the specific contribution of inanimate cells/components versus co-occurring metabolites remains insufficiently demonstrated.

Key research needs include better standardization and quality control (clear characterization of the inactivation process, composition, dose, and stability), and more rigorous, indication-specific human trials that meet the ISAPP requirement of demonstrated health benefit for a defined preparation. Additional gaps include comparative studies of live probiotics versus matched inactivated preparations, clearer attribution of effects to specific postbiotic constituents, and improved regulatory-relevant evidence frameworks (safety, efficacy, and reproducibility) to support translation beyond dietary supplement use. Several application areas are noted as promising but underdeveloped in the provided abstracts (e.g., oral health), and broader questions remain about optimal formulations, target populations, and long-term safety and effectiveness across diverse clinical contexts.

1. What conditions has Postbiotics been studied for?

  • Gastrointestinal conditions: diarrhea (multiple causes) and other gut-related symptoms; also discussed broadly in relation to gut microbiota homeostasis and gut barrier integrity.

  • Infant conditions: infant colic (mentioned as an area with clinical evidence).

  • Allergic/dermatologic conditions: atopic dermatitis (mentioned as an adult condition with evidence).

  • Metabolic diseases: obesity and type 2 diabetes mellitus; gestational diabetes mellitus is discussed as an area needing further study.

  • Immune and inflammatory dysregulation (broad): multiple abstracts emphasize immunomodulation and inflammation control via the gut microbiota–immune axis.

  • Cancer and type 1 diabetes (broad association): mentioned in the context that microbiota imbalance is linked to these diseases; postbiotics are discussed as having potential anti-cancer properties, but the abstracts do not provide specific clinical trial outcomes for these indications.

  • Oral disease: one abstract begins to discuss oral microbiota and tooth decay, but the provided text is incomplete and does not describe postbiotic interventions or outcomes.

2. Does it work in treating those conditions? Summarize the evidence.

  • Overall efficacy: promising but uneven and often not definitive. Multiple abstracts describe “increasing clinical studies” and “clinical trials” suggesting benefit, but they also emphasize that efficacy and safety require further study and that quality control/standardization is important for clinical implementation.

  • Diarrhea: One review notes clinical evidence for postbiotics to help “relief symptoms” in diarrhea of different causes. However, the abstracts do not provide trial sizes, effect sizes, or specific postbiotic preparations, so strength of evidence cannot be graded from the provided text alone.

  • Infant colic: Mentioned as having evidence for symptom relief. Again, the abstracts do not provide details on specific products, dosing, or magnitude of benefit.

  • Atopic dermatitis (adults): Mentioned as an area where evidence can be found for symptom relief. The abstracts do not specify whether outcomes were clinically meaningful or which postbiotic components were used.

  • Metabolic disease (obesity, type 2 diabetes): A metabolic-disease-focused review states that PPSP interventions (including postbiotics) “benefit metabolic diseases management,” and that clinical trials show benefits in patients with metabolic diseases. However, it also highlights that some strategies (e.g., gestational diabetes) and “health benefits of postbiotics” need further study, implying the evidence base is still developing and not fully settled.

  • Cancer and type 1 diabetes: The abstracts discuss these mainly as diseases associated with dysbiosis and mention potential anti-cancer properties of postbiotics, but they do not provide direct clinical evidence of treatment efficacy for these conditions.

  • Key limitation across indications: The ISAPP definition requires that a postbiotic be a preparation of inanimate microorganisms and/or their components that confers a health benefit. Several abstracts note inconsistent usage of the term and the need for regulatory clarity and standardization—meaning some studies/products labeled “postbiotic” may not meet the stricter ISAPP definition, complicating interpretation.

3. What health benefits does it have?

  • Immunomodulatory effects: Multiple abstracts describe postbiotics as modulating immune responses and interacting with the gut microbiota–immune system axis.

  • Anti-inflammatory effects: Reviews describe anti-inflammatory properties and the ability to help control inflammation.

  • Gut barrier support: Several abstracts emphasize improved intestinal/epithelial barrier integrity as a mechanism and benefit.

  • Antimicrobial activity: Mentioned as a bioactivity of postbiotic components (e.g., antimicrobial peptides).

  • Antioxidant effects: Cited as a pleiotropic effect in the literature.

  • Potential anti-cancer/anti-proliferative properties: Discussed as potential properties in reviews, but the abstracts do not provide specific clinical outcomes.

  • Metabolic benefits (via microbiome-related mechanisms): Reviews describe benefits in metabolic disease management, with proposed mechanisms including modulation of gut microbiota composition, regulation of microbial metabolites, and improved barrier function.

  • Practical/technological advantages vs live probiotics: Some abstracts claim postbiotics may offer advantages in safety, stability, and cost because they are inanimate and may be easier to standardize and distribute (though standardization is still highlighted as a need).

4. Does it have any downsides or side effects?

  • Safety profile is generally framed as potentially improved vs probiotics: One review states that because postbiotics do not contain live microorganisms, “the risks associated with their intake are minimized.” This suggests lower concern for issues tied to live microbial administration.

  • But safety is not fully established for all products/uses: Multiple abstracts explicitly state that “further study into its efficacy and safety is warranted” and emphasize the need for “quality control and standardization” for clinical implementation.

  • Definition/labeling inconsistency is a practical downside: ISAPP notes the term is inconsistently used; another abstract notes that in many cases the health contribution of inanimate microorganisms in probiotic products “has not been established.” This creates a risk that consumers may buy “postbiotic” products without proven benefits or consistent composition.

  • Specific adverse effects are not detailed in the provided abstracts: The abstracts do not list particular side effects (e.g., GI upset, allergic reactions) or quantify adverse event rates from trials.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not discuss pharmacogenomic interactions or specific human genetic variants that predict benefit or harm from postbiotics. They focus on general mechanisms (immune modulation, barrier function, microbial metabolites) and on the need for clearer definitions, standardization, and more efficacy/safety research. Based on these abstracts alone, no evidence-based claims can be made about gene-specific responders, non-responders, or increased risk in particular genetic subgroups.

References

  1. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics.
    Seppo Salminen, Maria Carmen Collado, Akihito Endo, Colin Hill, Sarah Lebeer, Eamonn M M Quigley, Mary Ellen Sanders, Raanan Shamir, Jonathan R Swann, Hania Szajewska, Gabriel Vinderola (2021) - Nature reviews. Gastroenterology & hepatology
  2. Probiotics, prebiotics, and postbiotics in health and disease.
    Jing Ji, Weilin Jin, Shuang-Jiang Liu, Zuoyi Jiao, Xiangkai Li (2023) - MedComm
  3. Unveiling the therapeutic symphony of probiotics, prebiotics, and postbiotics in gut-immune harmony.
    Pengjun Zhou, Chunlan Chen, Sandip Patil, Shaowei Dong (2024) - Frontiers in nutrition
  4. Postbiotics-A Step Beyond Pre- and Probiotics.
    Jakub Żółkiewicz, Aleksandra Marzec, Marek Ruszczyński, Wojciech Feleszko (2020) - Nutrients
  5. A comprehensive review of the application of probiotics and postbiotics in oral health.
    Aziz Homayouni Rad, Hadi Pourjafar, Esmaeel Mirzakhani (2023) - Frontiers in cellular and infection microbiology
  6. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review.
    Hang-Yu Li, Dan-Dan Zhou, Ren-You Gan, Si-Yu Huang, Cai-Ning Zhao, Ao Shang, Xiao-Yu Xu, Hua-Bin Li (2021) - Nutrients
  7. The Concept of Postbiotics.
    Gabriel Vinderola, Mary Ellen Sanders, Seppo Salminen (2022) - Foods (Basel, Switzerland)
  8. Postbiotics: Current Trends in Food and Pharmaceutical Industry.
    Priyamvada Thorakkattu, Anandu Chandra Khanashyam, Kartik Shah, Karthik Sajith Babu, Anjaly Shanker Mundanat, Aiswariya Deliephan, Gitanjali S Deokar, Chalat Santivarangkna, Nilesh Prakash Nirmal (2022) - Foods (Basel, Switzerland)
  9. The Current and Future Perspectives of Postbiotics.
    Bing Liang, Dongming Xing (2023) - Probiotics and antimicrobial proteins
  10. Postbiotics in Human Health: A Narrative Review.
    Linxi Ma, Huaijun Tu, Tingtao Chen (2023) - Nutrients
  11. Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond.
    Carrie A M Wegh, Sharon Y Geerlings, Jan Knol, Guus Roeselers, Clara Belzer (2019) - International journal of molecular sciences
  12. Health Benefits of Prebiotics, Probiotics, Synbiotics, and Postbiotics.
    Nasser Al-Habsi, Maha Al-Khalili, Syed Ariful Haque, Moussa Elias, Nada Al Olqi, Tasnim Al Uraimi (2024) - Nutrients
  13. Postbiotics and paraprobiotics: From concepts to applications.
    P F Cuevas-González, A M Liceaga, J E Aguilar-Toalá (2020) - Food research international (Ottawa, Ont.)
  14. Postbiotics as the new frontier in food and pharmaceutical research.
    Sahar Sabahi, Aziz Homayouni Rad, Leili Aghebati-Maleki, Narges Sangtarash, Mahdi Asghari Ozma, Atefeh Karimi, Hedayat Hosseini, Amin Abbasi (2023) - Critical reviews in food science and nutrition
  15. Gut microbiome-targeted therapies for Alzheimer's disease.
    Tao Zhang, Guangqi Gao, Lai-Yu Kwok, Zhihong Sun (2023) - Gut microbes
  16. Health Benefits of Consuming Foods with Bacterial Probiotics, Postbiotics, and Their Metabolites: A Review.
    Victor E Vera-Santander, Ricardo H Hernández-Figueroa, María T Jiménez-Munguía, Emma Mani-López, Aurelio López-Malo (2023) - Molecules (Basel, Switzerland)
  17. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.
    Natalia G Vallianou, Dimitris Kounatidis, Sotiria Psallida, Nikolaos Vythoulkas-Biotis, Andreas Adamou, Tatiana Zachariadou, Sofia Kargioti, Irene Karampela, Maria Dalamaga (2024) - Metabolites
  18. Microbiome and Postbiotics in Skin Health.
    Santosh Kumar Prajapati, Lalitha Lekkala, Dhananjay Yadav, Shalini Jain, Hariom Yadav (2025) - Biomedicines
  19. Postbiotics as potential new therapeutic agents for metabolic disorders management.
    Yasmina Bourebaba, Krzysztof Marycz, Malwina Mularczyk, Lynda Bourebaba (2022) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  20. A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity.
    Sylwia Smolinska, Florin-Dan Popescu, Magdalena Zemelka-Wiacek (2025) - Journal of clinical medicine


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!